HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Despite successful first year, cancer moonshot’s mission ‘nowhere near’ complete
-
- Symposium shows urothelial carcinoma at ‘forefront of practice-changing research’ Petros Grivas, MD, PhD; Vadim S. Koshkin, MD
- Algorithm may be ‘transformative’ for predicting GVHD after stem cell transplant
- Association of Community Cancer Centers names 2017-2018 president
- ‘Evidence is clear’: Moderate hypofractionation safe, effective for prostate cancer
- Evidence suggests prostate cancer biologically different in black men
- FDA: More adolescents with cancer should be included in adult trials
- Immunotherapies generate tremendous excitement for Merkel cell carcinoma
- MD Anderson immunology chair among Time magazine’s 100 most influential people
-
- NewYork-Presbyterian establishes glioblastoma research center
- Phase 2 trial of galinpepimut-S shows promise for high-risk patients with multiple myeloma
- Phase 2 trial of tarextumab for small cell lung cancer fails to meet primary, secondary endpoints
- Radiation oncologist joins Loyola University Health System board
- Remetinostat shows promise for early-stage cutaneous T-cell lymphoma
- Roswell Park Cancer Institute names department chairman
- Studies of veliparib for NSCLC, breast cancer fail to meet primary endpoints
- University of Iowa cancer center appoints deputy director
-
- Vaccine may prevent progression of DCIS to breast cancer
- Flat Earth, anti-Darwinism, the myth of global warming and PSA testing Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- FDA approves Bavencio for metastatic Merkel cell carcinoma
- FDA approves Zejula for maintenance treatment of gynecologic cancers
- FDA grants marketing authorization to genomic sequencing kit for suspected polycythemia vera
- FDA grants priority review to Blincyto for expanded ALL indication
- Liver metastasis from known malignant mixed Müllerian tumor Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD
- ASCO: Coordinated effort needed to provide high-quality care to sexual and gender minorities
-
- ASCO updates treatment guideline for potentially curable pancreatic cancer
- Circulating tumor DNA predicts pancreatic cancer survival
- Four frailty classification systems show good discrimination for elderly patients with cancer
- Hormone therapy does not affect survival in early-stage endometrial cancer
- Iron deficiency anemia appears linked to hearing loss in adults
- Long-term antibiotic use linked to increased risk for colorectal adenomas
- MRD negativity predicts long-term survival in CLL
- Newer NSCLC treatments confer modest increase in survival at high cost
-
- Ofatumumab plus salvage chemotherapy fails to improve outcomes in relapsed, refractory DLBCL
- Physician-aided deaths continue to rise in Oregon
- Pregnancy does not adversely affect survival among women with breast cancer
- Reduced-dose IMRT appropriate for induction chemotherapy responders with HPV-associated oropharyngeal cancer
- Some hospitalizations can be avoided for older adults with AML
- Use of prophylactic mastectomy increasing among younger women with early-stage breast cancer
- Anti–PD-1/PD-L1 therapy ‘rapidly becoming’ standard of care for Merkel cell carcinoma
- Atezolizumab prolongs OS for responders with triple-negative breast cancer
-
- Avelumab yields durable response at 1 year for advanced Merkel cell carcinoma
- Baseline factors predict survival benefit from BRAF/MEK inhibitor combination
- Choosing adjuvant melanoma therapy remains ‘controversial, tough’
- Combined immunotherapy shows early promise in advanced melanoma
- Genetic predisposition for subsequent neoplasms common in pediatric cancer survivors
- Incidence of certain cancers expected to decline among HIV–positive individuals
- Less sleep may increase risk for death in younger men with prostate cancer
- Molecular testing requires additional validation before ready for prime time in melanoma
-
- Multiple biopsies may help identify, treat resistance in NSCLC
- Nivolumab plus ipilimumab improves OS in advanced melanoma
- SBRT offers treatment option for elderly patients with lung cancer
- SUMMIT trial ‘guides development’ of pan-HER inhibitor in various cancers
- Are basket trials the most appropriate method to capitalize on increased rates of genomic sequencing?